Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Earth Science Tech's 3-Year RORE % for the quarter that ended in Mar. 2026 was 32.00%.
The industry rank for Earth Science Tech's 3-Year RORE % or its related term are showing as below:
ETST's 3-Year RORE % is ranked better than 76.18% of 936
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs ETST: 32.00
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Earth Science Tech 3-Year RORE % Related Terms
Earth Science Tech 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Earth Science Tech's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETST vs IXHL, BTAI, TLPH: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Earth Science Tech (ETST) has a 3-Year RORE % of 32.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Earth Science Tech and its competitors. According to the industry distribution chart, Earth Science Tech ranks #223 out of 936 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Earth Science Tech's 3-Year RORE % too high?
Earth Science Tech's current 3-Year RORE % is 32.00. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Earth Science Tech's value of 32.00 is 940.7% above this industry median. Based on the distribution chart, Earth Science Tech ranks #223 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Earth Science Tech has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's 3-Year RORE % compare to IXHL and BTAI?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #223 out of 936 companies for 3-Year RORE %. This places Earth Science Tech in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. Earth Science Tech's value of 32.00 is 940.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current 3-Year RORE % of 32.00 is 940.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Earth Science Tech and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current 3-Year RORE % is 32.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Based on GuruFocus' analysis, Earth Science Tech (ETST) is currently considered Possible Value Trap. The stock's GF Value™ is $0.24, compared to a current price of $0.14 — trading 43.8% below its estimated fair value. The current 3-Year RORE % is 32.00 and 940.7% above the Drug Manufacturers industry median of 3.08. Earth Science Tech's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Earth Science Tech (ETST), the current 3-Year RORE % is 32.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Earth Science Tech (ETST) Overvalued in 2026?
Based on GuruFocus' analysis, Earth Science Tech stock appears to be undervalued.
The current stock price of $0.14 is trading 43.8% below its estimated GF Value™ of $0.24.
GuruFocus considers Earth Science Tech to be Possible Value Trap.
Key valuation signals for ETST:
3-Year RORE %: 32.00
GF Value™: $0.24 vs. price of $0.14 (43.8% below fair value)
Industry Position: 940.7% above the Drug Manufacturers median (#223 of 936)
No single metric tells the full story. See the ETST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
37GF Score
Get the complete analysis for ETST
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
